|
ACVR1B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.69640000000327E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.193000E-04 |
| Normal-vs-Stage2 |
8.252800E-01 |
| Normal-vs-Stage3 |
7.6114000002736E-07 |
| Normal-vs-Stage4 |
3.5149999577655E-09 |
| Stage1-vs-Stage2 |
2.956200E-03 |
| Stage1-vs-Stage3 |
4.625500E-02 |
| Stage1-vs-Stage4 |
7.189500E-04 |
| Stage2-vs-Stage3 |
1.195520E-04 |
| Stage2-vs-Stage4 |
3.31249999996341E-06 |
| Stage3-vs-Stage4 |
2.370800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.7068000000029E-05 |
| Normal-vs-AfricanAmerican |
2.758200E-03 |
| Normal-vs-Asian |
1.78531999999176E-05 |
| Caucasian-vs-AfricanAmerican |
7.877800E-01 |
| Caucasian-vs-Asian |
2.593400E-01 |
| AfricanAmerican-vs-Asian |
6.860000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.160900E-03 |
| Normal-vs-Female |
1.5887299999906E-05 |
| Male-vs-Female |
1.677640E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.159780E-04 |
| Normal-vs-Age(41-60Yrs) |
6.20239999999939E-05 |
| Normal-vs-Age(61-80Yrs) |
1.623130E-04 |
| Normal-vs-Age(81-100Yrs) |
1.460080E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.163200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.992200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.661200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.729200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.060100E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.207400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.34440236720934E-11 |
| Classical-VS-Follicular |
3.499400E-03 |
| Classical-VS-Other |
1.240980E-01 |
| Classical-VS-Normal |
1.798040E-04 |
| Tall-VS-Follicular |
6.10622663543836E-15 |
| Tall-VS-Other |
4.668100E-02 |
| Tall-VS-Normal |
1.48769885299771E-14 |
| Follicular-VS-Other |
6.957400E-01 |
| Follicular-VS-Normal |
1.715360E-01 |
| Other-VS-Normal |
9.901600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.420640E-03 |
| Normal-vs-N1 |
7.89450000038272E-07 |
| N0-vs-N1 |
7.177000E-03 |
|
|
